Diffusion of interferon beta in Iran and its utilization in Tehran

Area of Science:

• Pharmacoeconomics and Health Policy
• Neurology and Clinical Therapeutics

Background:

• Limited research exists on the adoption of costly new medical treatments in low- and middle-income nations.
• Understanding drug diffusion patterns is crucial for healthcare planning and resource allocation.

Purpose of the Study:

• To investigate the diffusion and utilization of interferon beta for multiple sclerosis (MS) in Iran.
• To analyze treatment patterns in a cohort of 890 MS patients in Tehran.

Main Methods:

• Acquired national data on interferon beta drug diffusion (2000-2004) from the Ministry of Health.
• Collected patient utilization data from the Iranian MS Society (IMSS) registry in Tehran (2003-2005).

Main Results:

• Interferon beta exhibited rapid diffusion across all Iranian provinces by 2004, though less prevalent in poorer regions.
• In Tehran, 68% of IMSS-registered patients received interferon beta between 2003-2005.
• Insured patients showed significantly higher interferon beta usage compared to uninsured patients (p < 0.0001).

Conclusions:

• Interferon beta treatment has seen substantial growth in Iran.
• In Tehran, its use was concentrated among young, ambulatory patients with relapsing-remitting MS.
• Findings indicate a rational approach to drug utilization in managing MS in the study population.